Clinical trials present a new approach using immunotherapy

After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies could revolutionize the landscape of bladder cancer treatment.

Frontiers Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?

Cancers, Free Full-Text

New mRNA Pancreatic Cancer Vaccine Trial Starts Next Phase

In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome

Cancer Clinical Trials Cancer Research Institute

Biologics, Free Full-Text

IMMUNOTHERAPY ASSAYS, Top CRO for Bioanalysis - Marin Biologic Laboratories

Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy Trials

Frontiers Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

Frontiers Clinical cancer immunotherapy: Current progress and prospects

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy, Journal of Hematology & Oncology

Immunotherapy for Mesothelioma: Success Rates & Side Effects

Made-in-Canada CAR T Platform - BioCanRx